Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.
Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.
Patients want "more, better, faster" in regards to FDA-approved oncology drugs, Zujewski says.Any delay is a disadvantage to patients. Zujewski says she is in favor of international collaborations and standardization of information to ease the process.
Some advances that have been made have been in part due to retrospectively-collected data sets. Going forward, Zujewski says, trials should be developed that have the capacity for retrospective data collection so that, with diagnostic developers, the timeline for approval can be accelerated.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More